Boral Capital regular way IPOs have performed positively in the market: 2024 YTD IPOs have on average been up ~4.1% the first day following new issue day and up ~22.6% at 30 days post-IPO 3 ...

D. Boral Capital initiated coverage of MediciNova (MNOV) with a Buy rating and $9 price target The company is retasking an old drug, Ibudilast – originally used in Japan for asthma, to treat ...

NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- D. Boral Capital, a relationship-performance driven investment bank focused on high quality mid-market & growth issuers and investors, today provided a ...

Boral Capital, has initiated coverage on the Company with initial "Buy" recommendation. The information above is solely for informational purposes and is not intended as a solicitation to make ...